person · Reporting owner

Rizvi Syed Ali-aamir

Disclosed activity across 3 companies

Tapewire entity: 66474
SEC CIK: 0001897621

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Caribou Biosciences, Inc.CRBU · Entity 6445	Chief Medical Officer	February 21, 2023	February 23, 2023
ROCKET PHARMACEUTICALS, INC.RCKT · Entity 5627	Chief Medical Officer	February 11, 2026	February 13, 2026

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Caribou Biosciences, Inc.

Report date February 21, 2023 · Filed February 23, 2023

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Option to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $6.12 · Expires 2033-02-20	Direct	131,000	Reported balance After 2023-02-21 transaction · row 1 Instrument identity requires review; Table II rows are not merged. 1 source row Row 1 · 2023-02-21 · Grant · Acquired 131,000 · Balance 131,000 F1: The shares subject to this option will vest in equal monthly installments starting on the first monthly anniversary of the grant date until the option is fully vested on February 21, 2027, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.

Filing footnotes · ownership attribution and instrument terms

F1: The shares subject to this option will vest in equal monthly installments starting on the first monthly anniversary of the grant date until the option is fully vested on February 21, 2027, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.

ROCKET PHARMACEUTICALS, INC.

Report date February 11, 2026 · Filed February 13, 2026

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	407,874	Reported balance After 2026-02-11 transaction · row 1 Account or security details depend on footnotes; rows are not merged. 1 source row Row 1 · 2026-02-11 · Grant · Acquired 61,963 · Balance 407,874 F1: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2: Represents RSUs, one-third (1/3) of which will become fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years.
Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.24 · Expires 2036-02-11	Direct	93,037	Reported balance After 2026-02-11 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2026-02-11 · Grant · Acquired 93,037 · Balance 93,037 F3: This option represents a right to purchase a total of 93,037 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

Filing footnotes · ownership attribution and instrument terms

F1: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis.

F2: Represents RSUs, one-third (1/3) of which will become fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years.

F3: This option represents a right to purchase a total of 93,037 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer.

Past disclosures · reporting ended (1)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

Poseida Therapeutics, Inc.

Report date January 08, 2025 · Filed January 08, 2025

Section 16 reporting ended · disclosed 2025-01-08. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	0	Reported balance After 2025-01-08 transaction · row 1 1 source row Row 1 · 2025-01-08 · Other · Disposed 185,000 · Balance 0 F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent ("Merger Sub"). On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $9.00 per Share in cash (the "Cash Amount"), and (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2] F2: [continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.
Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.10 · Expires 2034-03-31	Direct	0	Reported balance After 2025-01-08 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2025-01-08 · Disposition to issuer · Disposed 250,000 · Balance 0 F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 4] F4: [Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5] F5: [Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof.

Filing footnotes · ownership attribution and instrument terms

F1: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent ("Merger Sub"). On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $9.00 per Share in cash (the "Cash Amount"), and (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2]

F2: [continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price.

F3: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 4]

F4: [Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5]

F5: [Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
February 11, 2026 Filed Feb 13, 2026 21:05 UTC	ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627	GrantStock Option (right to buy) · Derivative	93,037	$0.00 Strike: $3.24	$0.00	Disclosure SEC source: 0001140361-26-005409 · form4.xml · derivative · entry 2 Rizvi Syed Ali-aamir · CIK 0001897621 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 93,037 Underlying: Common Stock · 93,037 shares Expires 2036-02-11 F3 · derivative.exercise_date: This option represents a right to purchase a total of 93,037 shares of the Issuer's common stock, one-third of which will become fully vested and exercisable on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document
February 11, 2026 Filed Feb 13, 2026 21:05 UTC	ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627	GrantCommon Stock	61,963	$0.00	$0.00	Disclosure SEC source: 0001140361-26-005409 · form4.xml · nonDerivative · entry 1 Rizvi Syed Ali-aamir · CIK 0001897621 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 407,874 F1 · security: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. F2 · shares: Represents RSUs, one-third (1/3) of which will become fully vested on February 11, 2027, with the remaining shares vesting in equal quarterly installments over the following two years. F1 · balance_after: Holdings include Restricted Stock Units ("RSUs") that convert to common stock on a one-for-one basis. Read SEC document
October 06, 2025 Filed Oct 8, 2025 19:39 UTC	ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627	GrantStock Option (right to buy) · Derivative	383,854	$0.00 Strike: $3.18	$0.00	Disclosure SEC source: 0001140361-25-037683 · form4.xml · derivative · entry 3 Rizvi Syed Ali-aamir · CIK 0001897621 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 383,854 Underlying: Common Stock · 383,854 shares Expires 2035-10-06 F3 · kind: Represents non-qualified stock options ("NQSOs") that convert to common stock on a one-for-one basis. One-third (1/3) of such NQSOs will become fully vested on October 6, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. F3 · derivative.exercise_date: Represents non-qualified stock options ("NQSOs") that convert to common stock on a one-for-one basis. One-third (1/3) of such NQSOs will become fully vested on October 6, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document
October 06, 2025 Filed Oct 8, 2025 19:39 UTC	ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627	GrantCommon Stock	62,893	$0.00	$0.00	Disclosure SEC source: 0001140361-25-037683 · form4.xml · nonDerivative · entry 2 Rizvi Syed Ali-aamir · CIK 0001897621 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 345,911 F2 · kind: Represents RSUs that will vest in two installments. One-half (1/2) of the RSUs will become fully vested on October 6, 2026 and the remaining RSUs will vest on the second anniversary of the grant date, such that all of the shares underlying the award will be vested on the date two (2) years after the grant date, subject to the reporting person's continued employment with the Issuer or any of its subsidiaries. F2 · shares: Represents RSUs that will vest in two installments. One-half (1/2) of the RSUs will become fully vested on October 6, 2026 and the remaining RSUs will vest on the second anniversary of the grant date, such that all of the shares underlying the award will be vested on the date two (2) years after the grant date, subject to the reporting person's continued employment with the Issuer or any of its subsidiaries. F2 · price: Represents RSUs that will vest in two installments. One-half (1/2) of the RSUs will become fully vested on October 6, 2026 and the remaining RSUs will vest on the second anniversary of the grant date, such that all of the shares underlying the award will be vested on the date two (2) years after the grant date, subject to the reporting person's continued employment with the Issuer or any of its subsidiaries. Read SEC document
October 06, 2025 Filed Oct 8, 2025 19:39 UTC	ROCKET PHARMACEUTICALS, INC. RCKT · Entity 5627	GrantCommon Stock	283,018	$0.00	$0.00	Disclosure SEC source: 0001140361-25-037683 · form4.xml · nonDerivative · entry 1 Rizvi Syed Ali-aamir · CIK 0001897621 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 283,018 F1 · kind: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on October 6, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. F1 · shares: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on October 6, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. F1 · price: Represents restricted stock units ("RSUs") that convert to common stock on a one-for-one basis. One-third (1/3) of such RSUs will become fully vested on October 6, 2026, with the remaining shares vesting in equal quarterly installments over the following two years, subject to the reporting person's continued employment with the Issuer. Read SEC document
January 08, 2025 Filed Jan 8, 2025 14:10 UTC	Poseida Therapeutics, Inc. PSTX · Entity 84243	Disposition to issuerEmployee Stock Option (Right to Buy) · Derivative	250,000	$0.00 Strike: $3.10	$0.00	Disclosure SEC source: 0001415889-25-001083 · form4-01082025_070134.xml · derivative · entry 2 Rizvi Syed Ali-aamir · CIK 0001897621 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 250,000 shares Expires 2034-03-31 F3 · derivative.exercise_date: As of immediately prior to and conditioned upon the effective time of the effective time of the Merger, pursuant to the Merger Agreement, each outstanding option to purchase Shares (each, an "Option") became fully vested and exercisable, and to the extent not exercised prior to the effective time of the Merger, was cancelled and converted into the right to receive (a) an amount in cash (without interest and subject to deduction for any required withholding tax) equal to the product of (1) the excess, if any, of the Cash Amount over the exercise price per share of each such Option and (2) the number of Shares underlying such Option immediately prior to the effective time of the Merger and (b) one CVR in respect of each Share underlying such Option (the "Option Consideration"); provided, however, that if the exercise price per Share of any Option was equal to or greater than the Cash Amount, but less than $13.00 (any such option, an "Underwater Option"), [continues to Footnote 4] F4 · derivative.exercise_date: [Continues from Footnote 3] such Underwater Option was not entitled to any payment of the Cash Amount in respect thereof and each Underwater Option was converted into the right to receive the CVR included in the Option Consideration with respect to each Share underlying such Underwater Option and became entitled to receive, at each time a milestone payment becomes due and payable under the terms of the CVR Agreement, an amount in cash equal to the product of (a) the total number of Shares underlying such Underwater Option, multiplied by (b) the amount, if any, by which (1) the Cash Amount plus the amount of such milestone payment plus the amount of any other milestone payments that previously became due and payable under the terms of the CVR Agreement exceeds (2) the exercise price per Share with respect to such Underwater Option plus the Milestone Payment Amounts (as such term is defined in the CVR Agreement), [continues to Footnote 5] F5 · derivative.exercise_date: [Continues from Footnote 4] if any, previously paid pursuant to the CVR Agreement in respect of each CVR granted in respect of such Underwater Option; provided further, that any Option with an exercise price that was equal to or greater than $13.00, was cancelled immediately prior to the effective time of the Merger without any payment being made in respect thereof. Read SEC document
January 08, 2025 Filed Jan 8, 2025 14:10 UTC	Poseida Therapeutics, Inc. PSTX · Entity 84243	OtherCommon Stock	185,000	Not disclosed	Not disclosed	Disclosure SEC source: 0001415889-25-001083 · form4-01082025_070134.xml · nonDerivative · entry 1 Rizvi Syed Ali-aamir · CIK 0001897621 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 F1 · shares: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent ("Merger Sub"). On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $9.00 per Share in cash (the "Cash Amount"), and (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2] F2 · shares: [continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. F1 · price: Disposed of pursuant to the Agreement and Plan of Merger (the "Merger Agreement"), dated as of November 25, 2024, by and among Poseida Therapeutics, Inc. (the "Issuer"), Roche Holdings, Inc. ("Parent") and Blue Giant Acquisition Corp., a wholly owned subsidiary of Parent ("Merger Sub"). On January 8, 2025, Parent and Merger Sub completed a tender offer pursuant to the terms of the Merger Agreement for all outstanding shares of common stock of the Issuer (each, a "Share") for an offer price of (i) $9.00 per Share in cash (the "Cash Amount"), and (ii) one non-tradeable contingent value right (each, a "CVR") representing the right to receive certain contingent payments of up to an aggregate amount of $4.00 per Share, [continues to Footnote 2] F2 · price: [continues from Footnote 1] in cash, upon the achievement of specified milestones, subject to and in accordance with the terms of the Contingent Value Rights Agreement (the "CVR Agreement"), in each case, without interest, and subject to any applicable withholding taxes (the Cash Amount plus one CVR, collectively, the "Offer Price"). Merger Sub thereafter merged with and into the Issuer, with the Issuer continuing as the surviving corporation and a wholly owned subsidiary of Parent (the "Merger"). At the effective time of the Merger, each issued and outstanding Share (other than any Excluded Shares (as such term is defined in the Merger Agreement)) was cancelled in exchange for the right to receive the Offer Price. Read SEC document
April 01, 2024 Filed Apr 3, 2024 16:03 UTC	Poseida Therapeutics, Inc. PSTX · Entity 84243	GrantEmployee Stock Option (Right to Buy) · Derivative	250,000	$0.00 Strike: $3.10	$0.00	Disclosure SEC source: 0000950170-24-041039 · ownership.xml · derivative · entry 2 Rizvi Syed Ali-aamir · CIK 0001897621 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 250,000 Underlying: Common Stock · 250,000 shares Expires 2034-03-31 F2 · derivative.exercise_date: 12.5% of the shares subject to the stock option will vest and become exercisable on the six-month anniversary of the grant date, and the remaining shares will vest in 42 equal monthly installments thereafter. Read SEC document
April 01, 2024 Filed Apr 3, 2024 16:03 UTC	Poseida Therapeutics, Inc. PSTX · Entity 84243	GrantCommon Stock	185,000	$0.00	$0.00	Disclosure SEC source: 0000950170-24-041039 · ownership.xml · nonDerivative · entry 1 Rizvi Syed Ali-aamir · CIK 0001897621 · Chief Medical Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 185,000 F1 · kind: Represents shares issuable upon the vesting of restricted stock units granted pursuant to the Issuer's 2022 Inducement Plan. The RSUs are scheduled to vest in four equal annual installments. Read SEC document
February 21, 2023 Filed Feb 23, 2023 22:09 UTC	Caribou Biosciences, Inc. CRBU · Entity 6445	GrantOption to purchase Common Stock · Derivative	131,000	$0.00 Strike: $6.12	$0.00	Disclosure SEC source: 0001619856-23-000020 · wf-form4_167719014984142.xml · derivative · entry 1 Rizvi Syed Ali-aamir · CIK 0001897621 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 131,000 Underlying: Common Stock · 131,000 shares Expires 2033-02-20 F1 · derivative.exercise_date: The shares subject to this option will vest in equal monthly installments starting on the first monthly anniversary of the grant date until the option is fully vested on February 21, 2027, subject to the reporting person's continued service to the Issuer through the applicable vesting dates. Read SEC document
January 19, 2023 Filed Jan 20, 2023 21:13 UTC	Caribou Biosciences, Inc. CRBU · Entity 6445	SaleCommon Stock	5,627	$6.31	$35,506.37	Disclosure SEC source: 0001619856-23-000002 · wf-form4_167424918505378.xml · nonDerivative · entry 1 Rizvi Syed Ali-aamir · CIK 0001897621 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,373 F1 · shares: Represents the number of shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units as provided in standing "sell to cover" instructions. Read SEC document
January 25, 2022 Filed Jan 26, 2022 00:56 UTC	Caribou Biosciences, Inc. CRBU · Entity 6445	GrantOption to purchase common stock · Derivative	161,250	$0.00 Strike: $10.64	$0.00	Disclosure SEC source: 0001209191-22-004860 · doc4.xml · derivative · entry 2 Rizvi Syed Ali-aamir · CIK 0001897621 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 161,250 Underlying: Common stock · 161,250 shares Expires 2032-01-24 F2 · derivative.exercise_date: 1/4th of the shares subject to this option will vest on January 18, 2023 and an additional 1/48th of the aggregate number of shares subject to the option will vest on the corresponding day of each month thereafter, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. Read SEC document
January 25, 2022 Filed Jan 26, 2022 00:56 UTC	Caribou Biosciences, Inc. CRBU · Entity 6445	GrantCommon stock	60,000	$0.00	$0.00	Disclosure SEC source: 0001209191-22-004860 · doc4.xml · nonDerivative · entry 1 Rizvi Syed Ali-aamir · CIK 0001897621 · Chief Medical Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,000 F1 · shares: This reflects restricted stock units ("RSUs") that vest in four equal annual installments beginning on January 18, 2023, subject to the reporting person's continued services to the Issuer through the applicable vesting dates. The RSUs will be settled in stock within 30 days after each vesting date. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.